Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | GHSR | Q92847 | 2/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | MC4R | P32245 | 2/20 | 0.55 |
| ▸ | MC5R | P33032 | 1/20 | 0.55 |
| ▸ | MC3R | P41968 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721506 | 1.00 | KDM4E (0.61) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL1387764 | 1.00 | KDM4E (0.61) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL27542236 | 1.00 | KDM4E (0.61) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL3048070 | 1.00 | KDM4E (0.61) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL14906252 | 1.00 | KDM4E (0.61) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL1711405 | 1.00 | KDM4E (0.61) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29382469 | 1.00 | KDM4E (0.61) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29407002 | 0.99 | KDM4E (0.60) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29603261 | 0.98 | KDM4E (0.59) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29406743 | 0.97 | KDM4E (0.62) | KDM4EMEN1LMNAMPOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261215-B2 | Somatostatin prodrugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261215-B2 | Somatostatin prodrugs | VIP, SSTR4, SSTR5 | KDM4E 3109/4885MEN1 71/4885LMNA 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.